Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 80

1.

Gavestinel does not improve outcome after acute intracerebral hemorrhage: an analysis from the GAIN International and GAIN Americas studies.

Haley EC Jr, Thompson JL, Levin B, Davis S, Lees KR, Pittman JG, DeRosa JT, Ordronneau P, Brown DL, Sacco RL; GAIN Americas and GAIN International Investigators.

Stroke. 2005 May;36(5):1006-10. Epub 2005 Apr 14.

2.

Glycine antagonist in neuroprotection for patients with acute stroke: GAIN Americas: a randomized controlled trial.

Sacco RL, DeRosa JT, Haley EC Jr, Levin B, Ordronneau P, Phillips SJ, Rundek T, Snipes RG, Thompson JL; Glycine Antagonist in Neuroprotection Americas Investigators.

JAMA. 2001 Apr 4;285(13):1719-28.

PMID:
11277826
3.

Glycine antagonist (gavestinel) in neuroprotection (GAIN International) in patients with acute stroke: a randomised controlled trial. GAIN International Investigators.

Lees KR, Asplund K, Carolei A, Davis SM, Diener HC, Kaste M, Orgogozo JM, Whitehead J.

Lancet. 2000 Jun 3;355(9219):1949-54.

PMID:
10859040
4.

Effect of the Glycine Antagonist Gavestinel on cerebral infarcts in acute stroke patients, a randomized placebo-controlled trial: The GAIN MRI Substudy.

Warach S, Kaufman D, Chiu D, Devlin T, Luby M, Rashid A, Clayton L, Kaste M, Lees KR, Sacco R, Fisher M; GAIN MRI Substudy.

Cerebrovasc Dis. 2006;21(1-2):106-11. Epub 2005 Dec 9.

6.

Effect of blood pressure during the acute period of ischemic stroke on stroke outcome: a tertiary analysis of the GAIN International Trial.

Aslanyan S, Fazekas F, Weir CJ, Horner S, Lees KR; GAIN International Steering Committee and Investigators.

Stroke. 2003 Oct;34(10):2420-5. Epub 2003 Sep 18.

7.

Health care resource use after acute stroke in the Glycine Antagonist in Neuroprotection (GAIN) Americas trial.

Rundek T, Nielsen K, Phillips S, Johnston KC, Hux M, Watson D; GAIN Americas Investigators.

Stroke. 2004 Jun;35(6):1368-74. Epub 2004 Apr 29.

8.

Comparison of outcomes after intracerebral hemorrhage and ischemic stroke.

Chiu D, Peterson L, Elkind MS, Rosand J, Gerber LM, Silverstein MD; Glycine Antagonist in Neuroprotection Americas Trial Investigators.

J Stroke Cerebrovasc Dis. 2010 May;19(3):225-9. doi: 10.1016/j.jstrokecerebrovasdis.2009.06.002.

PMID:
20434051
9.

Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke.

Higashida RT, Furlan AJ, Roberts H, Tomsick T, Connors B, Barr J, Dillon W, Warach S, Broderick J, Tilley B, Sacks D; Technology Assessment Committee of the American Society of Interventional and Therapeutic Neuroradiology; Technology Assessment Committee of the Society of Interventional Radiology.

Stroke. 2003 Aug;34(8):e109-37. Epub 2003 Jul 17. Erratum in: Stroke. 2003 Nov;34(11):2774.

10.

Glycine antagonist (GV150526) in acute stroke: a multicentre, double-blind placebo-controlled phase II trial.

Lees KR, Lavelle JF, Cunha L, Diener HC, Sanders EA, Tack P, Wester P; GAIN Phase II European Study Group.

Cerebrovasc Dis. 2001;11(1):20-9.

PMID:
11173790
11.

Factors associated with intracerebral hemorrhage after thrombolytic therapy for ischemic stroke: pooled analysis of placebo data from the Stroke-Acute Ischemic NXY Treatment (SAINT) I and SAINT II Trials.

Cucchiara B, Kasner SE, Tanne D, Levine SR, Demchuk A, Messe SR, Sansing L, Lees KR, Lyden P; SAINT Investigators.

Stroke. 2009 Sep;40(9):3067-72. doi: 10.1161/STROKEAHA.109.554386. Epub 2009 Jul 16.

12.

Gavestinel produces no benefit for stroke patients, study finds.

[No authors listed]

Clin Resour Manag. 2001 Nov;2(11):173-5, 161.

PMID:
11727452
13.

Pharmacokinetics of a glycine site antagonist (gavestinel) following multiple dosing in patients with acute stroke.

Hoke JF, Dyker AG, Barnaby RJ, Lees KR.

Eur J Clin Pharmacol. 2000 Feb-Mar;55(11-12):867-72.

PMID:
10805066
14.

Health care resource use and stroke outcome. Multinational comparisons within the GAIN International trial.

Asplund K, Ashburner S, Cargill K, Hux M, Lees K, Drummond M; GAIN International Investigators.

Int J Technol Assess Health Care. 2003 Spring;19(2):267-77.

PMID:
12862185
15.

Clinical diagnosis of lacunar stroke in the first 6 hours after symptom onset: analysis of data from the glycine antagonist in neuroprotection (GAIN) Americas trial.

Phillips SJ, Dai D, Mitnitski A, Gubitz GJ, Johnston KC, Koroshetz WJ, Furie KL, Black S, Heiselman DE; GAIN Americas Investigators.

Stroke. 2007 Oct;38(10):2706-11. Epub 2007 Aug 23.

16.

Poststroke neurological improvement within 7 days is associated with subsequent deterioration.

Aslanyan S, Weir CJ, Johnston SC, Lees KR; GAIN International Steering Committee and Investigators.

Stroke. 2004 Sep;35(9):2165-70. Epub 2004 Jul 8.

17.

Sex as a predictor of outcomes in patients treated with thrombolysis for acute stroke.

Elkind MS, Prabhakaran S, Pittman J, Koroshetz W, Jacoby M, Johnston KC; GAIN Americas Investigators.

Neurology. 2007 Mar 13;68(11):842-8.

PMID:
17353472
18.

NXY-059 for the treatment of acute stroke: pooled analysis of the SAINT I and II Trials.

Diener HC, Lees KR, Lyden P, Grotta J, Davalos A, Davis SM, Shuaib A, Ashwood T, Wasiewski W, Alderfer V, HÃ¥rdemark HG, Rodichok L; SAINT I and II Investigators.

Stroke. 2008 Jun;39(6):1751-8. doi: 10.1161/STROKEAHA.107.503334. Epub 2008 Mar 27.

19.

How a sequential design would have affected the GAIN International Study of gavestinel in stroke.

Bolland K, Weeks A, Whitehead J, Lees KR; GAIN Interanational Steering Committee and the Investigators.

Cerebrovasc Dis. 2004;17(2-3):111-7. Epub 2003 Dec 23.

PMID:
14707409
20.

Excitatory amino acid antagonists for acute stroke.

Muir KW, Lees KR.

Cochrane Database Syst Rev. 2003;(3):CD001244. Review.

PMID:
12917902

Supplemental Content

Support Center